Literature DB >> 17483312

Influence of tumor cell and stroma sensitivity on tumor response to radiation.

Kazuhiko Ogawa1, Yves Boucher, Satoshi Kashiwagi, Dai Fukumura, David Chen, Leo E Gerweck.   

Abstract

In this study, we evaluated the role of tumor cell and tumor stroma sensitivity as determinants of radiation-induced tumor growth delay. A DNA double-strand break repair-defective DNA-PKcs(-/-) tumor cell line and its radioresistant DNA-PKcs(+/+)-transfected counterpart were used to initiate tumors in nude and hypersensitive severe combined immunodeficient (SCID) mice. Insertion of the human DNA-PKcs(+/+) gene substantially increased the intrinsic radioresistance of the DNA-PKcs(-/-) tumor cells and substantially decreased tumor response to radiation in both nude and hypersensitive SCID mice. Tumor cell radiosensitivity was the major determinant of tumor response in nude mice. In SCID mice, both tumor cell sensitivity and radiation-induced stromal damage contributed to response. The relative contribution of host and tumor cell sensitivity on tumor response was unchanged for single doses of 1 x 15 and 6 x 3 Gy-fractionated dose irradiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483312     DOI: 10.1158/0008-5472.CAN-06-4498

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited.

Authors:  Mónica García-Barros; Tin Htwe Thin; Jerzy Maj; Carlos Cordon-Cardo; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Authors:  Mitomu Kioi; Hannes Vogel; Geoffrey Schultz; Robert M Hoffman; Griffith R Harsh; J Martin Brown
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

3.  Spontaneous nonthymic tumors in SCID mice.

Authors:  Peigen Huang; Susan V Westmoreland; Rakesh K Jain; Dai Fukumura
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

Review 4.  Establishing the Impact of Vascular Damage on Tumor Response to High-Dose Radiation Therapy.

Authors:  Katherine D Castle; David G Kirsch
Journal:  Cancer Res       Date:  2019-08-19       Impact factor: 12.701

Review 5.  Proton RBE dependence on dose in the setting of hypofractionation.

Authors:  Thomas Friedrich
Journal:  Br J Radiol       Date:  2019-08-28       Impact factor: 3.039

6.  Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy.

Authors:  Everett J Moding; Katherine D Castle; Bradford A Perez; Patrick Oh; Hooney D Min; Hannah Norris; Yan Ma; Diana M Cardona; Chang-Lung Lee; David G Kirsch
Journal:  Sci Transl Med       Date:  2015-03-11       Impact factor: 17.956

Review 7.  Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.

Authors:  Everett J Moding; Yvonne M Mowery; David G Kirsch
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

Review 8.  Radiobiological basis of SBRT and SRS.

Authors:  Chang W Song; Mi-Sook Kim; L Chinsoo Cho; Kathryn Dusenbery; Paul W Sperduto
Journal:  Int J Clin Oncol       Date:  2014-07-05       Impact factor: 3.402

Review 9.  Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cell Cycle       Date:  2009-04-04       Impact factor: 4.534

10.  Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature.

Authors:  Ling Geng; Girish Rachakonda; D James Morré; Dorothy M Morré; Peter A Crooks; Vijayakumar N Sonar; Joseph L Roti Roti; Buck E Rogers; Suellen Greco; Fei Ye; Kenneth J Salleng; Soumya Sasi; Michael L Freeman; Konjeti R Sekhar
Journal:  FASEB J       Date:  2009-04-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.